NCT01096732View on ClinicalTrials.gov

Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)

PHASE2TerminatedINTERVENTIONAL

Enrollment

3

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions

Pancreatic Ductal Adenocarcinoma

Interventions

DRUG

GDC-0449

Gelatine capsules of 150mg.Taken O.D. for 14 days.

Trial Locations (1)

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

Sponsors

Lead Sponsor

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Roche Pharma AG

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Lisa Bax

OTHER

NCT01096732 - Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) | Biotech Hunter | Biotech Hunter